ResearcherUniversity of PisaActive in the last 2 years
Irene Pecora
Matched on ORCID iD 0000-0003-2644-2993; OpenAlex author ID A5056137515. Sources: OpenAlex.
Their work
- Papers
- 6
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 26
2019: 2 papers · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: none · 2024: 2 papers
Papers 6
- A pilot study of chlorambucil in pre-treated metastatic pancreatic adenocarcinoma patients bearing germline BRCA or other DNA damage repair system variants. Co-author DOI 10.1016/j.pan.2024.09.006↗
- The pan - COVID - AGICT study. The impact of COVID-19 pandemic on surgically treated pancreatic cancer patients. A multicentric Italian study. Co-author DOI 10.1016/j.suronc.2024.102081↗
- Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-p… Co-author DOI 10.1038/s41397-020-00203-7↗
- First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontier of age? Co-author DOI 10.1016/j.ejca.2020.06.031↗
- Combination Chemotherapy in Patients With Advanced Pancreatic Cancer With an Eastern Cooperative Oncology Group Performance Status of 2: Lights and Shadows of … Co-author DOI 10.1200/jco.19.00127↗
- Early Tumor Shrinkage and Depth of Response Evaluation in Metastatic Pancreatic Cancer Treated with First Line Chemotherapy: An Observational Retrospective Coh… Co-author DOI 10.3390/cancers11070939↗
Closest collaborators
The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Caterina Vivaldi · 4 shared papers, 2019–2021 · strength 0.39
- Paper Combination Chemotherapy in Patients With Advanced Pancreatic Cancer With an Eastern Cooperative Oncology Group Perform… DOI 10.1200/jco.19.00127↗
- Paper Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receivi… DOI 10.1038/s41397-020-00203-7↗
- Paper First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontie… DOI 10.1016/j.ejca.2020.06.031↗
- Silvia Catanese · 4 shared papers, 2019–2021 · strength 0.39
- Paper Combination Chemotherapy in Patients With Advanced Pancreatic Cancer With an Eastern Cooperative Oncology Group Perform… DOI 10.1200/jco.19.00127↗
- Paper Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receivi… DOI 10.1038/s41397-020-00203-7↗
- Paper First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontie… DOI 10.1016/j.ejca.2020.06.031↗
- Lorenzo Fornaro · 4 shared papers, 2019–2021 · strength 0.39
- Paper Combination Chemotherapy in Patients With Advanced Pancreatic Cancer With an Eastern Cooperative Oncology Group Perform… DOI 10.1200/jco.19.00127↗
- Paper Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receivi… DOI 10.1038/s41397-020-00203-7↗
- Paper First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontie… DOI 10.1016/j.ejca.2020.06.031↗
- Enrico Vasile · 4 shared papers, 2019–2021 · strength 0.39
- Paper Combination Chemotherapy in Patients With Advanced Pancreatic Cancer With an Eastern Cooperative Oncology Group Perform… DOI 10.1200/jco.19.00127↗
- Paper Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receivi… DOI 10.1038/s41397-020-00203-7↗
- Paper First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontie… DOI 10.1016/j.ejca.2020.06.031↗
- Umberto Peretti · 1 shared paper, 2024 · strength 0.18
- Marina Macchini · 1 shared paper, 2024 · strength 0.18
- Mario Scartozzi · 1 shared paper, 2024 · strength 0.18
- Andrea Spallanzani · 1 shared paper, 2024 · strength 0.18
- Catia Carconi · 1 shared paper, 2024 · strength 0.18
- Sara Lonardi · 1 shared paper, 2024 · strength 0.18
- Giulia Orsi · 1 shared paper, 2024 · strength 0.18
- Ingrid Garajová · 1 shared paper, 2024 · strength 0.18
- Rosella Spadi · 1 shared paper, 2024 · strength 0.18
- Luca Faloppi · 1 shared paper, 2024 · strength 0.18
- Michele Reni · 1 shared paper, 2024 · strength 0.18
- Eleonora Rofi · 1 shared paper, 2021 · strength 0.11
- Marzia Del Re · 1 shared paper, 2021 · strength 0.11
- Romano Danesi · 1 shared paper, 2021 · strength 0.11
- Kalliopi Andrikou · 1 shared paper, 2020 · strength 0.09
- Giulia Rovesti · 1 shared paper, 2020 · strength 0.09
- Vincenzo Formica · 1 shared paper, 2020 · strength 0.09
- Daniela Campani · 1 shared paper, 2019 · strength 0.07
- Emanuele F. Kauffmann · 1 shared paper, 2019 · strength 0.07
- Andrea Cacciato Insilla · 1 shared paper, 2019 · strength 0.07
- Niccolò Napoli · 1 shared paper, 2019 · strength 0.07
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.